Navigation Links
Instanyl(R) (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer Pain
Date:9/11/2009

med

Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated total sales of EUR3.4 billion in 2008 and an adjusted EBITDA of EUR1.2 billion.

    For more information visithttp://www.nycomed.com

    About the study

    - A multinational, open-label, crossover trial comparing Instanyl(R) and
      Actiq(R) for breakthrough cancer pain in patients receiving chronic
      opioid treatment.

    - The trial investigated the efficacy of Instanyl compared to Actiq as
      well as ease of administration and patient preference.

    - Primary efficacy measurement was time to onset of meaningful pain
      relief.

    - Of 196 patients enrolled and 139 randomised, 86 patients completed the
      trial.

    Results showed that:

    - 25.3% of episodes showed meaningful pain relief (greater than or equal
      to 33% reduction in PI score) at 5 minutes after treatment with
      Instanyl versus 6.8% with Actiq.

    - 51% of the Instanyl treated patients had a meaningful pain relief
      (greater than or equal to 33% reduction in PI score) at 10 minutes
      versus 23
'/>"/>
SOURCE Nycomed
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window
2. University of Michigan Study Shows SEQUENOMs MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
3. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
4. Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors
5. Angiomax Will Retain Decision Resources Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI
6. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
7. Study Shows No Standardized Approach to Epidural Steroid Injections for Back Pain
8. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
9. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
10. Siemens Introduces New Standard of Care for Breast Ultrasound
11. Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
(Date:10/20/2014)... , Oct. 20, 2014 Pharmaceutic Labs ... facility in Albany, NY for ... The company meets and/or exceeds the FDA standards for ... 21 CFR Part 211. The 10,000 ... highest levels of quality assurance and quality control. The ...
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma Corp. ... will report its third quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... Anlit Advanced Nutrition Supplements , an ... for children, will present new and innovative products at ... 2012 in Geneva, Switzerland. Anlit will showcase new ... at Stand 3500. The company will present, among others, ...
... 2012  Luminex Corporation (NASDAQ: LMNX ) today announced ...  Financial and operating highlights include the following: , ... increase over the first quarter of 2011 , First ... over the first quarter of 2011 , First quarter ...
Cached Medicine Technology:Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012 2Luminex Corporation Reports First Quarter 2012 Results 2Luminex Corporation Reports First Quarter 2012 Results 3Luminex Corporation Reports First Quarter 2012 Results 4Luminex Corporation Reports First Quarter 2012 Results 5Luminex Corporation Reports First Quarter 2012 Results 6Luminex Corporation Reports First Quarter 2012 Results 7Luminex Corporation Reports First Quarter 2012 Results 8
(Date:10/20/2014)... Myoderm announced today ... of their CentralSource service. Matthew will ... turnkey drug sourcing, distribution, and management service for ... years of industry experience, in both business development ... of their international success to help clients manage ...
(Date:10/20/2014)... California (PRWEB) October 20, 2014 Final Cut ... the release of the Citrus theme for FCPX filmmakers ... would use to describe the Citrus theme” Says Christina Austin, ... easy to look so professional.” , Citrus comes with all ... with the template are: four transitions for added style, a ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... 19, 2014 Visual Impact Frequency ... just been released to the public generating a ... building and fitness community. The commotion surrounding the ... Vin Delmonico prompting an investigative review. , "Many ... what is commonly known as a training 'plateau' ...
Breaking Medicine News(10 mins):Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... fruitful, lead in ongoing investigation into salmonella outbreak , , ... U.S. government investigation into salmonella-tainted tomatoes has not yet ... said Monday they are now focusing their trace-back efforts ... , "The cluster is linked to the same ...
... PITTSBURGH, June 16 Mylan Inc. (NYSE: ... Inc., has,received tentative approval from the U.S. Food ... Application (ANDA) for Irbesartan and,Hydrochlorothiazide Tablets, 150 mg/12.5 ... Hydrochlorothiazide Tablets, indicated for the treatment,of hypertension, are ...
... have found a new family of therapeutic agents that ... growth of breast cancer cells. The results of the ... The Endocrine Society,s 90th Annual Meeting in San Francisco. ... therapeutic called TPBM and related compounds are likely to ...
... of agents that inhibit the growth of estrogen-dependent breast ... of the Endocrine Society, has opened an avenue of ... , "This cell-based study is exciting because it suggests ... that remain dependent on estrogen for growth but are ...
... could be the next generation of treatments, researchers say ... identified a new group of compounds that might one ... to fight estrogen-fueled breast cancer. , "This is a ... Dr. Len Lichtenfeld, deputy chief medical officer of the ...
... June 16 The National Center for Healthcare,Leadership ... Gabow, MD, chief,executive officer of Denver Health, as ... for her significant and lasting contributions,to healthcare. Under ... healthcare system that achieves organizational,excellence while treating at-risk ...
Cached Medicine News:Health News:FDA Narrowing Tainted Tomato Probe to One Cluster 2Health News:FDA Narrowing Tainted Tomato Probe to One Cluster 3Health News:Future hope for patients with breast cancers resistant to tamoxifen 2Health News:Team discovers new inhibitors of estrogen-dependent breast cancer cells 2Health News:New Molecule Discovery Shows Promise Against Tamoxifen-Resistant Breast Cancers 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 3Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 4
... The NU-5510 DHD AutoFlow Direct ... HEPA filtration guarantying the greatest control ... cycles, both at 95C wet decontamination ... are exceptionally useful for cell line ...
... CO2 Incubators by Cedco enhance ... precise temperature and CO2 control. ... RH% is displayed digitally. Functions ... are displayed digiton large, easy ...
... By combining the corrosion resistance ... antibacterial properties of copper, SANYO offers ... sterile, long-lasting and maintenance-free. The sterile ... valid test results and the safety ...
ArcticTemp Upright Freezer -20C. Quick, even freezing. Heavy duty compressor. Deep door racks. Front gated bottom shelf. Interior light. Locks One year warranty on unit and 5 year warranty on compres...
Medicine Products: